JPS5225013A - Insulin pharmaceutical for nasal administration - Google Patents
Insulin pharmaceutical for nasal administrationInfo
- Publication number
- JPS5225013A JPS5225013A JP51055965A JP5596576A JPS5225013A JP S5225013 A JPS5225013 A JP S5225013A JP 51055965 A JP51055965 A JP 51055965A JP 5596576 A JP5596576 A JP 5596576A JP S5225013 A JPS5225013 A JP S5225013A
- Authority
- JP
- Japan
- Prior art keywords
- nasal administration
- insulin pharmaceutical
- insulin
- pharmaceutical
- nasal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
PURPOSE: A novel insulin solution capable of self-medication of insulin by nasal administration..
COPYRIGHT: (C)1977,JPO&Japio
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB34576/75A GB1527605A (en) | 1975-08-20 | 1975-08-20 | Insulin preparation for intranasal administration |
GB34576/75 | 1975-08-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5225013A true JPS5225013A (en) | 1977-02-24 |
JPS6030651B2 JPS6030651B2 (en) | 1985-07-17 |
Family
ID=10367351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51055965A Expired JPS6030651B2 (en) | 1975-08-20 | 1976-05-14 | Insulin preparations for nasal administration |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPS6030651B2 (en) |
BE (1) | BE841871A (en) |
DE (1) | DE2620446A1 (en) |
FR (1) | FR2321275A1 (en) |
GB (1) | GB1527605A (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5145405A (en) * | 1974-10-16 | 1976-04-17 | Unyusho Kowan Gijutsu Kenkyush | JIBAN KAIRYOKOHO |
JPS53115510A (en) * | 1977-12-19 | 1978-10-09 | Kitagawa Iron Works Co | Support structure made by hardening weak soil |
JPS53115509A (en) * | 1977-12-19 | 1978-10-09 | Kitagawa Iron Works Co | Method of changing weak ground into stable ground |
JPS59112925A (en) * | 1982-12-10 | 1984-06-29 | シンテツクス(ユ−・エス・エ−・)インコ−ポレイテイド | Nasal administration composition |
JPS6289627A (en) * | 1985-06-04 | 1987-04-24 | Chugai Pharmaceut Co Ltd | Anemic remedy for nasotracheal administration |
JPH02213522A (en) * | 1989-02-14 | 1990-08-24 | Kajima Corp | Construction method for base of structure |
WO2012096276A1 (en) * | 2011-01-13 | 2012-07-19 | 株式会社カネカ | Percutaneous absorption promoter and external skin preparation |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2917535C2 (en) * | 1979-04-30 | 1986-10-30 | Hoechst Ag, 6230 Frankfurt | Insulin solutions resistant to denaturation |
JPS58501125A (en) * | 1981-07-17 | 1983-07-14 | ノルデイスク・インスリンラボラトリウム | Stable aqueous therapeutic insulin preparation and method for producing the same |
CH657779A5 (en) * | 1982-10-05 | 1986-09-30 | Sandoz Ag | GALENIC COMPOSITIONS CONTAINING CALCITONIN. |
AU572815B2 (en) * | 1982-12-29 | 1988-05-19 | Armour Pharmaceutical Company | Pharmaceutical calcitonin compositions for intranasal application |
JPS59163313A (en) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | Peptide hormone composition for nasal administration |
US4548922A (en) * | 1983-06-06 | 1985-10-22 | Beth Israel Hospital | Drug administration |
US4746508A (en) * | 1983-06-06 | 1988-05-24 | Beth Israel Hospital Assn. | Drug administration |
DE3443877A1 (en) * | 1984-06-09 | 1985-12-12 | Hoechst Ag | Insulin preparations, process for their preparation, and their use |
US4658830A (en) * | 1984-08-08 | 1987-04-21 | Survival Technology, Inc. | Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms |
AU584184B2 (en) * | 1985-04-15 | 1989-05-18 | Eli Lilly And Company | An improved method for administering insulin |
CA1274774A (en) * | 1985-04-15 | 1990-10-02 | Kenneth S. Su | Method for administering insulin |
US4692441A (en) * | 1985-08-16 | 1987-09-08 | Merck & Co., Inc. | Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities |
US4731360A (en) * | 1985-08-16 | 1988-03-15 | Merck & Co., Inc. | Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments |
DK179286D0 (en) * | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | INSULIN PREPARATION |
CA1291036C (en) * | 1986-04-23 | 1991-10-22 | Edwin I. Stoltz | Nasal administration of drugs |
US5179079A (en) * | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
NZ222907A (en) * | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
US5112804A (en) * | 1987-04-01 | 1992-05-12 | Temple University Of The Commonwealth System Of Higher Education | Pharmaceutical composition and method of intranasal administration |
CA1335076C (en) * | 1987-04-01 | 1995-04-04 | Hanna R. Kowarski | Pharmaceutical composition and method for intranasal administration |
US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Pharmaceutical oral, enteral or by-inhalation dosage form for suppressing an autoimmune response associated with type i diabetes |
JPH04126437U (en) * | 1991-05-10 | 1992-11-18 | 八木アンテナ株式会社 | optical receiver |
US5338837A (en) * | 1991-12-13 | 1994-08-16 | The Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making same |
US5693769A (en) * | 1991-12-13 | 1997-12-02 | Transcell Technologies, Inc. | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
US5639866A (en) * | 1993-02-23 | 1997-06-17 | Princeton University | Single-step formation of multiple glycosidic linkages |
IL108748A0 (en) * | 1993-02-23 | 1994-08-26 | Univ Princeton | Solution and solid-phase formation of glycosidic linkages |
US5747445A (en) * | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
US5506203C1 (en) * | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
US5830853A (en) | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
US6632456B1 (en) | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
US6794357B1 (en) | 1993-06-24 | 2004-09-21 | Astrazeneca Ab | Compositions for inhalation |
IS1796B (en) * | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
CZ295827B6 (en) | 1994-03-07 | 2005-11-16 | Nektar Therapeutics | Method for aerosolizing a dose of insulin, insulin composition and use thereof |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US6165976A (en) * | 1994-06-23 | 2000-12-26 | Astra Aktiebolag | Therapeutic preparation for inhalation |
JP3687993B2 (en) * | 1994-06-24 | 2005-08-24 | シスメックス株式会社 | Insulin standard solution |
US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
PL320856A1 (en) | 1994-12-22 | 1997-11-10 | Astra Ab | Aerosol drug preparations |
US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
US5780014A (en) * | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US20030203036A1 (en) | 2000-03-17 | 2003-10-30 | Gordon Marc S. | Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients |
US7575761B2 (en) | 2000-06-30 | 2009-08-18 | Novartis Pharma Ag | Spray drying process control of drying kinetics |
DE10114178A1 (en) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinc-free and low-zinc insulin preparations with improved stability |
US6653492B2 (en) | 2001-05-02 | 2003-11-25 | Novo Nordick A/S | Preparation of bile acids |
GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
DE10227232A1 (en) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Sour insulin preparations with improved stability |
CA2740685C (en) | 2008-10-17 | 2018-09-11 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
JP5973918B2 (en) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
JP6199186B2 (en) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
RU2650616C2 (en) | 2011-08-29 | 2018-04-16 | Санофи-Авентис Дойчланд Гмбх | Pharmaceutical combination for use in glycemic control in patients with type 2 diabetes mellitus |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
HRP20230470T1 (en) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL62232C (en) * | 1900-01-01 | |||
US3096249A (en) * | 1960-05-10 | 1963-07-02 | Samuel J Prigal | Emulsion composition |
-
1975
- 1975-08-20 GB GB34576/75A patent/GB1527605A/en not_active Expired
-
1976
- 1976-05-08 DE DE19762620446 patent/DE2620446A1/en not_active Withdrawn
- 1976-05-14 BE BE167070A patent/BE841871A/en not_active IP Right Cessation
- 1976-05-14 JP JP51055965A patent/JPS6030651B2/en not_active Expired
- 1976-05-14 FR FR7614707A patent/FR2321275A1/en active Granted
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5145405A (en) * | 1974-10-16 | 1976-04-17 | Unyusho Kowan Gijutsu Kenkyush | JIBAN KAIRYOKOHO |
JPS5416325B2 (en) * | 1974-10-16 | 1979-06-21 | ||
JPS53115510A (en) * | 1977-12-19 | 1978-10-09 | Kitagawa Iron Works Co | Support structure made by hardening weak soil |
JPS53115509A (en) * | 1977-12-19 | 1978-10-09 | Kitagawa Iron Works Co | Method of changing weak ground into stable ground |
JPS59112925A (en) * | 1982-12-10 | 1984-06-29 | シンテツクス(ユ−・エス・エ−・)インコ−ポレイテイド | Nasal administration composition |
JPS6289627A (en) * | 1985-06-04 | 1987-04-24 | Chugai Pharmaceut Co Ltd | Anemic remedy for nasotracheal administration |
JPH02213522A (en) * | 1989-02-14 | 1990-08-24 | Kajima Corp | Construction method for base of structure |
WO2012096276A1 (en) * | 2011-01-13 | 2012-07-19 | 株式会社カネカ | Percutaneous absorption promoter and external skin preparation |
JP5906194B2 (en) * | 2011-01-13 | 2016-04-20 | 株式会社カネカ | Skin preparation |
Also Published As
Publication number | Publication date |
---|---|
FR2321275B1 (en) | 1979-04-13 |
DE2620446A1 (en) | 1977-03-03 |
GB1527605A (en) | 1978-10-04 |
FR2321275A1 (en) | 1977-03-18 |
BE841871A (en) | 1976-11-16 |
JPS6030651B2 (en) | 1985-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5225013A (en) | Insulin pharmaceutical for nasal administration | |
CA1027005A (en) | Inhaler for powdered medicament | |
GB1554157A (en) | Stable insulin preparation for intra nasal administration | |
JPS5241214A (en) | Method of making preparations for oral administration | |
JPS51139617A (en) | A process for preparing a remedy for intestinal infectious diseases | |
JPS5228922A (en) | Medicine mixture for animals | |
AU504182B2 (en) | Pharmaceutical dosage forms | |
JPS52108028A (en) | Remedies for dysacousis | |
JPS5228926A (en) | Process for film coating of medicines | |
GR61158B (en) | N-tetrahydrofurfuryl-noroxymorphone,salts thereof by addition of acid,pharmaceutical mediums containing them and process for the preparation thereof | |
JPS51123815A (en) | A process for preparing coated solid medicines | |
JPS52128232A (en) | Drugs for alleviating toxicity to kidneys | |
JPS5228946A (en) | Amino acid infusion | |
JPS545046A (en) | Cephalosporin preparation for oral administration | |
JPS51125719A (en) | A method for preparing a liquid medicine for internal use | |
JPS51136818A (en) | Method for preparing stable prostaglandine pharma ceuticals | |
JPS51151387A (en) | Process for preparing 2-alpha-maltosyl -maltosyl glucose | |
JPS5214779A (en) | Novel process for preparing pericyazine | |
JPS5241210A (en) | Method of making insulin preparations for rectal administration | |
JPS5569510A (en) | Carcinostatic agent | |
JPS5212919A (en) | A method for preparing a stable prostaglandin f2alpha injection | |
JPS5498339A (en) | Carcinostatic agent | |
JPS5225017A (en) | Process for preparing a pharmaceutical for rectal administration | |
JPS5251362A (en) | Preparation of optically active pyrrolidine derivatives | |
JPS5215808A (en) | Process for preparing a drug against athlet s foot |